诺华制药2026年展望：营收微增但利润承压，新药研发与市场拓展并行

Core Insights - Novartis projects low single-digit growth in net sales for 2026, while core operating income may decline in low single digits due to generic drug competition [1] - The company reported Q4 2025 revenue of $13.34 billion, a year-over-year increase of 1.4%, but $740 million below expectations; non-GAAP EPS was $2.03, exceeding expectations by $0.03 [1] - Management warns of profit decline in 2026 but expresses confidence in returning to growth in 2027 [1] Institutional Views - On February 17, 2026, TD Cowen raised Novartis' stock price target from $160 to $180, maintaining an "outperform" rating based on the progress of the core pipeline and solid 2025 guidance [2] Recent Developments - Novartis announced positive final analysis results for the Phase III study of the new drug ACR-368 for IgA nephropathy on February 13, 2026, and plans to apply for traditional approval from the FDA [3] - The company aims to have seven key data readouts in 2026 and continues to enhance its pipeline through acquisitions, including recent purchases of Avidity and Tourmaline [3] - The Chinese market is expected to contribute $4.2 billion in revenue by 2025, with a radioactive drug production facility in Zhejiang Haiyan projected to commence operations by the end of 2026 to support regional growth [3] Stock Performance - Over the week from February 13 to 20, 2026, Novartis' stock price fluctuated by 0.40%, with a high of $167.86 and a low of $161.75; the latest closing price on February 20, 2026, was $161.82, reflecting a single-day decline of 1.28% [4] - The price-to-earnings ratio (TTM) stands at 22.63 [4]